Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04306367 · ClinicalTrials.gov registry record · Phase 2
Study of Pembrolizumab and Olaparib in Bile Duct Cancer
A Phase 2 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT04306367 is a Phase 2 study that has completed, run by Georgetown University. The registered enrollment target is 14 participants.
The verdict
NCT04306367, a Phase 2 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The investigators propose an open label, one-arm study to assess the safety and efficacy of olaparib and pembrolizumab in patients with cholangiocarcinoma who have progressed on or cannot tolerate gemcitabine-based therapy.
Interventions
- DRUG Pembrolizumab
- DRUG Olaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-04-01 |
| Est. Completion | 2024-12-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04306367
The ClinicalTrials.gov registry entry for NCT04306367 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04306367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04306367 about?
NCT04306367 is a clinical study titled "Study of Pembrolizumab and Olaparib in Bile Duct Cancer". The investigators propose an open label, one-arm study to assess the safety and efficacy of olaparib and pembrolizumab in patients with cholangiocarcinoma who have progressed on or cannot tolerate gemcitabine-based therapy.
What is the current status of trial NCT04306367?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2020-04-01. Estimated completion is 2024-12-19.
What interventions are being tested in trial NCT04306367?
The interventions under investigation include: Pembrolizumab (DRUG), Olaparib (DRUG).
Who is sponsoring clinical trial NCT04306367?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.